Cuesta, A M <br/><br/>
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.  [electronic resource] 

 -  Scientific reports  07 2019 
 - 10062 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-019-46448-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic beta-Antagonists--pharmacology<br/>Apoptosis<br/>Cell Nucleus--metabolism<br/>Central Nervous System Neoplasms--complications<br/>Hemangioblastoma--complications<br/>Humans<br/>Hypoxia-Inducible Factor 1, alpha Subunit--metabolism<br/>Molecular Targeted Therapy<br/>Mutation--genetics<br/>Neovascularization, Pathologic<br/>Propanolamines--pharmacology<br/>Signal Transduction<br/>Tumor Cells, Cultured<br/>Von Hippel-Lindau Tumor Suppressor Protein--genetics<br/>von Hippel-Lindau Disease--complications